Author: Benzinga Newsdesk | August 14, 2025 06:44am
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.68) by 11.76 percent. This is a 6.25 percent increase over losses of $(0.64) per share from the same period last year.